JZL 195

Fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) mediate the hydrolysis of the endocannabinoids arachidonoyl ethanolamide (AEA) and 2-arachidonoylglycerol (2-AG), respectively. JZL 195 is a potent inhibitor of both FAAH and MAGL (IC50s = 2 and 4 nM, respectively). It poorly inhibits neuropathy target esterase and ABHD6 and does not inhibit other brain serine hydrolases. JZL 195 displays time-dependent inhibition of FAAH and MAGL in vivo, consistent with a covalent mechanism of activation. The in vivo inhibitory actions of JZL 195 against FAAH and MAGL are comparable to those of the selective inhibitors PF-3845 (Cay-13279) and JZL 184 (Cay-13158), respectively. Through its inhibitory actions, JZL 195 simultaneously augments brain levels of AEA and 2-AG, producing antinociceptive, cataleptic, and hypomotility effects like those produced by direct CB1 agonists.Formal Name: 4-nitrophenyl 4-(3-phenoxybenzyl)piperazine-1-carboxylate. CAS Number: 1210004-12-8. Molecular Formula: C24H23N3O5. Formula Weight: 433.5. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 5 mg/ml, DMSO: 1.25 mg/ml. lambdamax: 273 nm. SMILES: O=C(OC1=CC=C([N+]([O-])=O)C=C1)N(CC2)CCN2CC3=CC=CC(OC4=CC=CC=C4)=C3. InChi Code: InChI=1S/C24H23N3O5/c28-24(32-22-11-9-20(10-12-22)27(29)30)26-15-13-25(14-16-26)18-19-5-4-8-23(17-19)31-21-6-2-1-3-7-21/h1-12,17H,13-16,18H2. InChi Key: QNYRAEKLMNDRFY-UHFFFAOYSA-N. License: Sold under license from The Scripps Research Institute..